Celldex Therapeutics Inc. (NASDAQ: CLDX) shares rose on Thursday Nov 17 with lower trade volume than normal after a number of analysts weighed in on the investing value of the stock with a downgraded rating.
Meanwhile, stocks opened flat this morning, struggling for direction in early trade ahead of congressional testimony by Federal Reserve Chairwoman Janet Yellen. Ahead of an appearance before the Joint Economic Committee, Yellen said an interest-rate hike could come “relatively soon,”
The S&P 500 SPX, +0.25% fell less than 0.1% to 2,176.85 while Dow Industrials DJIA, -0.05% fell 9 points to 18,858. The Nasdaq Composite COMP, +0.18% declined 0.1% to 5,291.48.
Analysts at Zacks Investment Research downgraded shares of Celldex Therapeutics Inc. (NASDAQ: CLDX) from Buy to Hold in a research note to investors today. With a rating of Hold on the shares, the company has a 52-week high of $18.62. The one-year price target of $7.33 is higher than the opening price of $4.37, that has caused a number of other analysts to comment on the company in recent days. Important and major changes in the company’s operations, future direction or industry can cause downgrades as the analysts consider that the future prospects for the security have diminished from the original recommendation.
Celldex Therapeutics Inc. (NASDAQ: CLDX) shares last traded at $4.42, a jump of $0.04 or 0.80% compared to the previous closing price. Opening at $4.37, they varied from $4.36 and $4.44 throughout the day.
Celldex Therapeutics Inc. (NASDAQ: CLDX) now has a market cap of 447.01B.
Celldex Therapeutics Inc. (NASDAQ: CLDX) Average Daily Trading Volume
The stock’s average daily volume is 2,551,540 shares out of a total float 100,659,000 and some 177,687 shares traded hands yesterday, below normal. Trading volume is likely to increase in the next few days as momentum traders often use swings in trading volume to identify substantial volume accumulation or dissemination by institutional investors.
As with all possible breakouts, investors look for volume to be at least 40%-50% above normal on the breakout to indicate that fund managers and other professional investors are jumping in.
Institutional sponsorship is defined by ownership of a stock by mutual funds, banks, pension funds and other large institutions.
Institutional investors such as these have teams of analysts that research thousands of stocks, so it is good confirmation to see them buying a stock you are researching.
Celldex Therapeutics Inc. (NASDAQ: CLDX) Moving Averages
A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.
This is because the average acts like a floor (support), so the price bounces up off of it.
In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.
By following the activity of these professional investors and how they influence moving averages, traders are able to make make educated trades.
With that in mind, Celldex Therapeutics Inc. (NASDAQ: CLDX) now has a 50-day MA of $3.72 and 200-day MA of $4.06. It has traded in a 52-week range between $2.85 – 18.620 and today’s last price is 76.29%% lower than the 52 week high of $18.62.
Indeed, earnings growth is among the most critical things to look at in regards to stock investing and, accordingly, investors identify companies that have raised their earnings at least 25% or more for the past 3 years.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.